BSE filing, NSE: APLLTD. Summary written from the filing by ALFA Finder's alert engine.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹797.85
- Market cap
- ₹15,683 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 22.6×Sector 45.9×
- Promoter holding
- 69.87%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Board Meeting Date
Alembic Pharmaceuticals scheduled its board meeting for November 4, 2026, to consider unaudited Q1/H1 FY27 results. Trading window re-opens 48 hours post-declaration.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.26 Cr
Alembic Pharmaceuticals' subsidiary, Alembic Global Holding SA, incorporated a new wholly-owned subsidiary, Alvesta Pharmaceuticals FZCO, in the UAE for Rs. 0.26 Crore.
- Value
- ₹0.26 Cr
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.23 Cr
Alembic Pharmaceuticals' wholly-owned subsidiary, Alembic Global Holding SA, incorporated a new step-down subsidiary, Alvesta Pharmaceuticals FZCO, in Dubai for AED 1 Lakh (approx. ₹0.23 Crore).
- Value
- ₹0.23 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP. This drug is therapeutically equivalent to the reference product Ciprodex Otic Suspension.
Alembic Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern under SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Other annual report announcements
All →Garment Mantra Lifestyle Annual Report
Garment Mantra Lifestyle submitted a revised FY2025-26 Annual Report correcting five observations, including related-party transaction labels and auditor location. No financial event or new business activity is reported.
Inani Securities Annual Report
Inani Securities submitted its 32nd Annual Report for FY 2025-26 with the AGM notice, AGM set for 23 September 2026. The filing is the full annual report and cover letter.
Datakosa Annual Report
Bodhtree Consulting filed its 44th Annual Report for FY 2025-26 with the AGM notice for September 9, 2026. It reports no new transaction or financial event.
Morarka Finance Annual Report
Morarka Finance filed its 2025-26 Annual Report and AGM notice for the July 15, 2026 meeting. Agenda includes Pranay Morarka's Managing Director appointment and remuneration.
Venlon Enterprises Annual Report
Venlon Enterprises filed its 2025-26 Annual Report ahead of its September 18, 2026 AGM. The notice seeks approval for three related-party transactions.
Gujarat Peanut and Agri Products Annual Report
Gujarat Peanut And Agri Products filed a resubmitted Annual Report for FY 2025-26 after an earlier filing went under the wrong module. The report shows turnover of Rs. 38,932.71 Lakhs and PAT of Rs. 738.30 Lakhs.